Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24360324 | 1.00 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL28768828 | 0.88 | KIF11 (0.48) | KIF11DNMT1 | |
| SCHEMBL26923900 | 0.87 | KIF11 (0.40) | KIF11DNMT1 | |
| SCHEMBL24360332 | 0.86 | KIF11 (0.40) | KIF11DNMT1 | |
| SCHEMBL24374519 | 0.86 | KIF11 (0.40) | KIF11DNMT1 | |
| SCHEMBL8370224 | 0.85 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL21084958 | 0.85 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL20185747 | 0.85 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL31599210 | 0.84 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL24360331 | 0.82 | KIF11 (0.46) | KIF11DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| EP-4232034-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2023-08-30 | — | — | EP | disclosed |
| CN-116670116-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116635032-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | KIF11 1650/4885DNMT1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.